NEW YORK, August 23, 2017 /PRNewswire/ --
If you want a Stock Review on TEVA, ENDP, IONS, or AMRN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. The Drug Manufacturers space consists of establishments primarily engaged in one or more of the following: manufacturing biological and medical products; processing botanical drugs and herbs; isolating active medical principles from botanical drugs and herbs; and manufacturing pharmaceutical products intended for internal and external consumption. DailyStockTracker.com has issued research reports on: Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International PLC (NASDAQ: ENDP), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), and Amarin Corp. PLC (NASDAQ: AMRN). Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:
Shares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd saw a slight drop of 0.18%, ending Tuesday's trading session at $17.01. The stock recorded a trading volume of 14.91 million shares. The Company's shares are trading 40.14% below their 50-day moving average. Moreover, shares of Teva Pharma, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have a Relative Strength Index (RSI) of 16.54.
On August 16th, 2017, research firm Citigroup downgraded the Company's stock rating from 'Buy' to 'Neutral'.
On August 18th, 2017, Teva Pharma announced the launch of generic Axiron®1 (testosterone) topical solution CIII, 30 mg/1.5 mL, in the US. Testosterone topical solution CIII is a prescription medicine used to treat adult males who have low or no testosterone due to certain medical conditions. It is supplied in a metered dose pump with an underarm applicator. Visit us today and access your complete report on TEVA for free at:
Dublin, Ireland headquartered Endo International PLC's stock declined 1.64%, closing the day at $8.38. A total volume of 6.94 million shares was traded, which was above their three months average volume of 6.37 million shares. The Company's shares are trading 21.32% below their 50-day moving average. Additionally, shares of Endo, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have an RSI of 32.92.
On August 08th, 2017, Endo reported Q2 2017 financial results. For the quarter, revenues were $876 million; net loss from continuing operations was $696 million; and diluted loss per share from continuing operations was $3.12. As of June 30th, 2017, the Company had $617 million in unrestricted cash; debt of $8.3 billion; net debt of approximately $7.7 billion; and a net debt to adjusted EBITDA ratio of 4.3.
On August 09th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with a decrease of the target price from $15 a share to $9 a share. The complimentary research report on ENDP can be accessed at:
On Tuesday, shares in Carlsbad, California headquartered Ionis Pharmaceuticals Inc. recorded a trading volume of 974,664 shares. The stock ended the day 5.16% higher at $48.88. The Company's shares have advanced 8.29% in the previous three months and 2.20% on an YTD basis. The stock is trading above its 200-day moving average by 4.87%. Furthermore, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 46.04.
On August 17th, 2017, research firm Evercore ISI initiated an 'Outperform' rating on the Company's stock, with a target price of $65 per share.
On August 17th, 2017, Ionis Pharma announced that management will present a Company overview at the following investor conferences: the Southern California Investor Conference on August 24th, 2017, in Newport Beach, California; the 2017 Wells Fargo Healthcare Conference on September 06th, 2017, in Boston, Massachusetts; and the 15th Annual Morgan Stanley Global Healthcare Conference on September 13th, 2017, in New York. Register for free on DailyStockTracker.com and download the research report on IONS at:
Dublin, Ireland-based Amarin Corp. PLC's stock rose 0.33%, finishing yesterday's session at $3.04 with a total trading volume of 1.18 million shares. The Company's shares have advanced 4.11% in the previous three months. The stock is trading below its 200-day moving average by 6.77%. Additionally, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have an RSI of 30.83.
On August 02nd, 2017, Amarin announced financial results for the three and six months ended June 30th, 2017. For Q2 2017, net product revenue was $44.9 million and GAAP net loss was $13.6 million. For the six months ended June 30th, 2017, net product revenue was $79.3 million and GAAP net loss was $34.6 million. At June 30th, 2017, the Company reported cash and cash equivalents of $85.5 million. Get free access to your research report on AMRN at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA